The aim of the study was to evaluate the 3 years incidence of cardiometabolic risk factors, such as impaired fasting glucose, reduced high-density lipoprotein (HDL)-cholesterol, increased plasma triglycerides or blood pressure as well as impaired glucose tolerance in overweight or obese (ow/ob) and normal body weight (nbw) subjects metabolically normal at baseline. Subjects from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) study were analyzed. We analyzed 284 nbw and 152 ow/ob subjects who, at baseline, did not show any of the above-mentioned cardiometabolic risk factors. At 3 years, these parameters were re-evaluated. Intima-media thickness (IMT) of the common carotid artery (CCA) was echographically measured. At follow-up, the incidence of one or more cardiometabolic risk factors was 57.2% in ow/ob vs. 31.7% in nbw (P < 0.0001). After adjustment for age, sex, menopause status, lifestyle parameters, insulin sensitivity, and fasting insulinemia, BMI remained significantly linked to the development of one or more cardiometabolic risk factors (P = 0.02). An increased BMI at follow-up was significantly associated with the development of cardiometabolic alterations, in both nbw and ow/ob groups (P = 0.04). Ow/ob subjects who, at 3 years follow-up, remained metabolically normal, showed a less favourable cardiometabolic profile, when compared to nbw counterparts. In ow/ob metabolically normal males and females, intima-media of the common carotid at follow-up was thicker than in nbw (P = 0.03 for males, P = 0.04 for females). In conclusion, metabolically normal obese subjects show a higher incidence of cardiometabolic risk factors, in a short follow-up period. Weight gain is significantly associated with the development of these factors, in both nbw and ow/ob subjects.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/oby.2012.69 | DOI Listing |
Lancet Reg Health Eur
February 2025
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Background: The evidence on the link between cardiometabolic diseases (CMDs) and motor neuron diseases (MNDs) remains inconsistent. We aimed to determine whether there is an association of CMDs, namely, any cardiovascular disease, cardiac arrhythmia, heart failure, thromboembolic disease, hypertension, cerebrovascular disease, ischemic heart disease, diabetes mellitus type 2, and hypercholesterolemia with the risk and progression of MNDs.
Methods: We included 1463 MND patients (amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), progressive spinal muscular atrophy (PSMA), and unspecified MND) diagnosed from January 1, 2015, to July 1, 2023, in Sweden according to the Swedish Motor Neuron Disease Quality Registry (i.
Nutr Metab Insights
January 2025
Department of Community Nutrition, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
Background: Metabolic syndrome (MetS) is defined as the existence of metabolic profile risk factors and impaired glycemic status such as dysglycemia, hyperinsulinemia, insulin resistance (IR), dyslipidemia, and hypertension. Several studies demonstrated that a diet that promotes proper nutritional intake; plays a critical role in the prevention and control of MetS. Our goal for conducting this cross-sectional study was to investigate any potential relationships between the nutrient adequacy ratio (NAR) and cardiometabolic risk variables within obese individuals.
View Article and Find Full Text PDFFront Nutr
December 2024
Clinical Epidemiology Research Office, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
Aims: To explore the effect of plasma homocysteine (Hcy) on cardiometabolic multimorbidity (CMM) among Chinses adults.
Methods: This study combined a community-based cross-sectional study with a 1:1 matched case-control study using propensity score method among adults aged over 30 years in six districts randomly selected from Hunan Province, China. We recruited 5,258 people, of whom 4,012 met the study criteria were enrolled.
J Clin Transl Endocrinol
March 2025
Department of Internal Medicine III, Clinical Division of Endocrinology and Metabolism, Gender Medicine Unit, Medical University of Vienna, General Hospital Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Purpose: We aimed to assess the changes in body fat distribution, intraorgan lipid accumulation, and cardiometabolic risk factors after 6 months of gender-affirming hormone therapy (GAHT) in transgender men (TM) and transgender women (TW).
Methods: Conducted at the Medical University of Vienna between 2019 and 2022, the study included 15 TW and 20 TM. We conducted magnetic resonance imaging and spectroscopy to determine the visceral (VAT) and subcutaneous adipose tissue (SAT) amounts, the VAT/SAT ratio, and the intraorgan lipid content (liver, pancreas, myocardium), bloodwork, and an oral glucose tolerance test at baseline and after 6 months of GAHT.
Int J Prison Health (2024)
January 2025
Department of Nutrition and Dietetics, Bandirma Onyedi Eylul University, Balikesir, Turkiye.
Purpose: This study aims to evaluate the obesity and cardiometabolic disease risks of incarcerated men and to determine the related factors.
Design/methodology/approach: This study was cross-sectional and 139 incarcerated men were included. Data were collected using a questionnaire containing the Descriptive Information Form and the Pittsburgh Sleep Quality Index.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!